TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02063438

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericostal suture technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracostal suture technique
Study: NCT02704377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Undergo HRV and wear accelerometer to assess therapy complications
Description: Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo iDXA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01199900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
Study: NCT01791010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Study: NCT02704377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01908699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium 314d Modified Release Tablets
Description: Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
Study: NCT01697501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interleukin 28B testing
Description: Blood sampling for IL28B genotyping
Study: NCT00292903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief interpersonal psychotherapy
Description: IPT-B sessions include evaluation of participants' level of depression, identification of any difficulties or problems that participants may be experiencing, and review of how to manage these problems using skills learned during treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated referral for treatment as usual
Description: F-TAU includes providing verbal and written information regarding depressive symptoms and a referral for treatment at a behavioral health clinic.
Study: NCT03939494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Encounter
Description: Contact will be made with participants via Face Time or Skype.
Study: NCT03053232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Purse string suture device
Description: Using purse string suture device to close gastrointestinal perforation under endoscopy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoclips
Description: Using endoclips to close gastrointestinal perforation under endoscopy.
Study: NCT03987685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oratopo
Description: Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
Study: NCT01791010

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Training sham
Description: Conducting fake training with the aim of blind the control group
Study: NCT01247038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metal on ceramic articulation
Description: Metal on ceramic articulation against metal-on-metal articulation using the same Recap Acetabular cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal-on-Metal
Description: Metal on Metal articulation
Study: NCT03953118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Oral Product
Description: Oral azithromycin dosed at 1 gram per week for 3 weeks
Study: NCT03822715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate restricted dietary intervention
Description: Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care aromatase inhibitors
Description: standard of care aromatase inhibitors
Study: NCT01534221

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix drug eluting stent
Description: Biomatrix drug eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix drug eluting stent
Description: Biomatrix drug eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix drug eluting stent
Description: Biomatrix drug eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix drug eluting stent
Description: Biomatrix drug eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix drug eluting stent
Description: Biomatrix drug eluting stent
Study: NCT02003898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic MiniMed 530G Insulin Pump
Study: NCT03953118

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral
Description: Oral placebo tablet
Study: NCT00095628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00845780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: withdrawal or continuation of amiodarone therapy
Description: withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: withdrawal or continuation of amiodarone therapy
Description: withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
Study: NCT00939757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral tablet
Study: NCT03913442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.8 mg or 0.6 mg orally once daily
Description: Colchicine 0.8 mg orally once daily for 1.5 months, and then 0.6 mg once daily for the remainder of the time (1.5 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo 0.8 mg or 0.6 mg orally once daily for 3 months
Study: NCT02877537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plethysmography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plethysmography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plethysmography
Study: NCT01716325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-management weight loss plan endorsement.
Description: Self-management weight loss plan endorsement.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional
Description: Weight loss, comparator - no ICT support; conventional live workshops for weight loss
Study: NCT01978873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen deprivation therapy
Description: LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
Study: NCT02508870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab as per the schedule described in individual cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab as per the schedule described in individual cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab as per the schedule described in individual cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab as per the schedule described in individual cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab as per the schedule described in individual cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab as per the schedule described in individual cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Participants will receive azacitidine as per the schedule described in individual cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Participants will receive azacitidine as per the schedule described in individual cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Participants will receive azacitidine as per the schedule described in individual cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Participants will receive azacitidine as per the schedule described in individual cohort.
Study: NCT04483349

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT03123874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterile pump set-up
Description: Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterile pump set-up
Description: Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mother's Own pump set-up
Description: Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mother's Own pump set-up
Description: Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
Study: NCT00453258

Intervention type: OTHER
Intervention: Eye Examination
Description: Subjects receiving eye examination
Study: NCT02641873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: 240 mg twice daily (480 mg total daily dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate
Description: 200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
Study: NCT00697827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interspinous Spacer device
Description: Device: In-Space

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interspinous Process Distraction Device
Description: Device: X STOP
Study: NCT01851876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endometrial injury
Description: Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
Study: NCT01889758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.
Study: NCT01575886

Intervention type: OTHER
Group type: OTHER
Intervention: Teachable Moment Communication Process
Description: The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teachable Moment Communication Process
Description: The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.
Study: NCT02272985

Intervention type: OTHER
Group type: OTHER
Intervention: [15O]H2O PET-CT scan
Description: All participants will undergo 3 \[15O\]H2O PET-CT scans during the hemodialysis study session

Intervention type: OTHER
Group type: OTHER
Intervention: NIRS (Invos)
Description: All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
Study: NCT04585581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: time-restricted eating
Description: Participants will be asked to limit the time-window for their daily energy intake to a maximum of 10 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity exercise
Description: Participants will be encouraged to exercise with high intensity 2-3 times per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard clinical care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard clinical care
Study: NCT04493138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO
Study: NCT03583515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-Specific Personalized Normative Feedback
Description: Participants will receive personalized normative feedback about drinking.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Social Media Personalized Normative Feedback
Description: Participants will receive personalized normative feedback about social media use.
Study: NCT01280955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
Study: NCT00938223

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 4-peptide and 12-peptide melanoma vaccines
Description: Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.~Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.~Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.~All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 4-peptide and 12-peptide melanoma vaccines
Description: Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.~Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.~Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.~All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN).
Study: NCT01314157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isostretching
Description: 12 interventions (two times per week) for 45 minutes
Study: NCT02370771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological sampling
Description: Biological sampling to identify by label-free proteomic analysis of a combination of serum biomarkers in patients with Erosive and non erosive hand Osteoarthritis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiographic evaluation
Description: Radiographic assessments using Bone Mineral Analyser and Hand MRI will be done in patients with Erosive and non erosive hand Osteoarthritis
Study: NCT02163122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Allergen Challenge
Description: Cat allergen (FelD1) applied directly to the nasal tissues

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Allergen Challenge
Description: Cat allergen (FelD1) applied directly to the nasal tissues

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Allergen Challenge
Description: Cat allergen (FelD1) applied directly to the nasal tissues

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Exposure Chamber
Description: The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Exposure Chamber
Description: The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat allergen (FelD1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat allergen (FelD1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat allergen (FelD1)
Study: NCT02730208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor/Ivacaftor
Description: TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: IVA 150 mg tablet.
Study: NCT02084082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin ER FDC
Description: 1x Linagliptin/Metformin FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin ER FDC
Description: 1x Linagliptin/Metformin FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin ER FDC
Description: 1x Linagliptin/Metformin FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin ER FDC
Description: 1x Linagliptin/Metformin FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1x Linagliptin tablet
Study: NCT02730208

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to TEZ/IVA fixed-dose combination tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to IVA tablet.
Study: NCT02084082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1x Linagliptin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1x Linagliptin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1x Linagliptin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: 2x Metformin ER tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: 2x Metformin ER tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: 2x Metformin ER tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: 2x Metformin ER tablets
Study: NCT02862782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG (Ovitrelle 250 mcg mcg - Merck Serono)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG (Ovitrelle 250 mcg mcg - Merck Serono) + GnRH agonist (Decapeptyl 0.2mg - Ferring Gmgh)